• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthPfizer

Pfizer wants you to call its COVID vaccine Comirnaty. How the name came about

By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
By
Chris Morris
Chris Morris
Former Contributing Writer
Down Arrow Button Icon
August 23, 2021, 12:12 PM ET

Fresh off its full approval by the FDA, the Pfizer COVID-19 vaccine (also referred to as the Pfizer-BioNTech vaccine) would now like to be known as Comirnaty.  

It’s a request with which few people are likely to comply.

The brand name for the Pfizer vaccine is a mouthful, but it’s not new. In fact, it has been around since last December. (There’s even a name for the generic version of the drug, whenever that hits the market: tozinameran.) But where did it come from?

Comirnaty (pronounced “koe-mir-na-tee”) is actually a car wreck of several words, all of which are centered around the pandemic and the breakthrough technology that enabled scientists to develop a vaccine so fast.

“Comirnaty…represents a combination of the terms COVID-19, mRNA, community, and immunity, to highlight the first authorization of a messenger RNA (mRNA) vaccine, as well as the joint global efforts that made this achievement possible,” said Pfizer in announcing EU authorization last year.

The name, which you might guess if you say it out loud, is meant to evoke community (even if it sounds like it’s being said by the woman in the “Ermahgerd” meme).

To break it down more, “Co” comes from COVID-19. “Mirna” is an adulterated version of mRNA. And “-ty” blends in the community and immunity themes.

As for that generic name, which is even more of a mouthful, “tozina-“ is a prefix required by the World Health Organization, while “meran” is a required suffix for mRNA vaccines.

If you’re not a fan of Comirnaty, it could have been…well, better or worse. You decide. Among the reported rejected names Pfizer and BioNTech considered were Covuity, RnaxCovi, Kovimerna, and RNXtract.

As for Moderna’s COVID vaccine? It doesn’t have a name in the U.S. yet, but the odds-on favorite is Spikevax. The European Medicines Agency approved that name last month. When and if the FDA gives Moderna’s treatment full approval, it will rule on the name as well.

More health care and Big Pharma coverage from Fortune:

  • The most common COVID Delta variant symptoms in adults and kids
  • Google Health chief leaves to become CEO of health tech company Cerner
  • South Dakota sees the country’s largest two-week COVID surge
  • What side effects can you expect from the COVID-19 vaccine booster shots?
  • New U.S. COVID cases are up 52%. See where cases are rising the fastest

Subscribe to Fortune Daily to get essential business stories straight to your inbox each morning.

About the Author
By Chris MorrisFormer Contributing Writer

Chris Morris is a former contributing writer at Fortune, covering everything from general business news to the video game and theme park industries.

See full bioRight Arrow Button Icon

Latest in Health

HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
9 hours ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
10 hours ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
12 hours ago
Healthmeal delivery
Factor Meals Review 2025: Tester Approved
By Christina SnyderDecember 12, 2025
1 day ago
Donald Trump
HealthHealth Insurance
‘Tragedy in the making’: Top healthcare exec on why insurance will spike to subsidize a tax cut to millionaires and billionaires
By Nick LichtenbergDecember 12, 2025
1 day ago
HelloFresh meal delivery service.
Healthmeal delivery
HelloFresh Review : We Tasted Everything so You Don’t Have To
By Christina SnyderDecember 12, 2025
1 day ago

Most Popular

placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
2 days ago
placeholder alt text
Success
Apple cofounder Ronald Wayne sold his 10% stake for $800 in 1976—today it’d be worth up to $400 billion
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Success
40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Economy
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shake-up
By Jason MaDecember 12, 2025
1 day ago
placeholder alt text
Economy
For the first time since Trump’s tariff rollout, import tax revenue has fallen, threatening his lofty plans to slash the $38 trillion national debt
By Sasha RogelbergDecember 12, 2025
1 day ago
placeholder alt text
Success
Apple CEO Tim Cook out-earns the average American’s salary in just 7 hours—to put that into context, he could buy a new $439,000 home in just 2 days
By Emma BurleighDecember 12, 2025
1 day ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.